Reach us at (573) 881-5080

The basis for this technological advance was the recognition of an overlapping RFamide-like pharmacophore within the melanocortin pharmacophore (HFRW) that mediated cardiovascular activity.  The development of a synthetic approach to suppress RFamide activity formed the basis for the patent.  Continued advancements led to the discovery (patent-pending) of a platform technology for producing drug-like peptides with multiple applications.

The advantage of TCI Peptide's approach over other attempts to develop melanocortins as drugs is that our analogs are free of adverse cardiovascular side effects, and are more drug-like (more stable in plasma, orally active, predictable PK).  Previous attempts to develop melanocortin-based drugs failed due to cardioascular side-effects in both experimental studies and clinical trials. A U.S. patent for the suppression of cardiovascular  side-effects in melanocortin-based therapeutics has issued and related patents are pending.  

IP PORTFOLIO


Issued-USPTO  #8,541,545

Stabilized Melanocortin Ligands

08/30/2010

Granted-EU  #10 812 701.0

Stabilized Melanocortin Ligands

08/30/2010

Pending-USPTO  #14/384,694

Melanocortin Analogs Having Enhanced Activity and Transport

3/20/2012

Pending-EU  #13760918.6

Melanocortin Analogs Having Enhanced Activity and Transport

3/20/2012

Provisional-PCT;  #1020847; Anti-Microbial Peptides

9/19/2015;


Provisional-USPTO  #008077-0907964

Angiotensin(1-7) Analogs & Methods Relating Thereto

9/17/2015

Tensive Controls Cancer Cachexia Peptide platform